New York, May 22, 2026, 19:04 EDT
- Femasys jumped 29.9% to close at 43.8 cents. After hours, prices looked more volatile.
- Trading volume was several times higher than the stock’s usual daily average.
- FEMY is still under Nasdaq’s $1 minimum bid even after the rally.
Femasys Inc. shares rallied about 30% on Friday, a late-session pop for the women’s health stock as U.S. small caps pushed higher heading into Memorial Day weekend.
Shares finished at 43.8 cents, gaining from the prior 33.73 cents close, per Investing.com. The stock moved between 33 cents and 45.49 cents on the day. After hours, the quote was 51.02 cents, according to the same source.
Femasys (NASDAQ: FEMY) is still trading under $1 and has until July 13, 2026, to meet Nasdaq’s minimum bid rule. The company said it needs to close at or above $1 for 10 straight days to comply.
Volume stood out. Robinhood’s quote page put Femasys trading at 14.89 million shares, way above its average of about 536,350, a sign the rally wasn’t just normal trading but likely got a push from speculators. Volume is just the count of shares traded. In small stocks like this, jumps in volume can swing prices hard.
No new Femasys filings showed up in the last 48 hours in checks of available sources. The latest SEC current report came on May 13, when Femasys put out an updated investor presentation for meetings with investors, analysts and others.
The most recent news from the company was earlier this month. On May 13, Femasys said its FemHSG catheter got CE Mark approval, letting it move forward with commercial partners to sell the fertility product in Europe. With the approval, the device meets European safety, health and environmental standards for sale.
Femasys is aiming to grow its business with in-office fertility and birth-control offerings. In a quarterly update on May 8, CEO Kathy Lee-Sepsick pointed to “clinical, regulatory and commercial progress” on both the FemBloc and FemaSeed platforms. She also noted the launch of enrollment for the FINALE pivotal trial of FemBloc.
Femasys posted a 24.5% jump in first-quarter sales to $424,889, up from $341,264 last year, helped by FemBloc sales, the company said. Net income came in at $846,100, a figure that included gains from fair value changes in financial instruments. Net income for common stockholders was $328,646.
Cash and listing concerns are front and center. Femasys had $5.39 million in cash and cash equivalents at March 31, with management saying the company expects those funds to last through the third quarter of 2026. In its 10-Q, Femasys flagged the need for additional financing, cautioning that a new stock sale could dilute existing shareholders.
Reverse split still possible for Femasys. The company said investors signed off on a split in the range of 1-for-2 to 1-for-25, leaving the board with flexibility to decide the exact terms before May 1, 2027. A reverse split can boost the share price but won’t fix the company’s operations or cash.
The field is crowded and the companies don’t match up one-to-one. Progyny targets employers with fertility and family-building plans. CooperSurgical focuses on reproductive-care, fertility and women’s health products. Femasys is a smaller name offering in-office gynecology devices. Progyny
Femasys jumped well beyond the broader indexes, which all rose Friday. The Russell 2000 moved up 0.9%, the Nasdaq Composite added 0.2% and the S&P 500 climbed 0.4%, AP market data showed.
U.S. stock markets are closed for Memorial Day on Monday, May 25, so trading resumes Tuesday, May 26, according to Nasdaq. Femasys goes into the long weekend with some momentum, but it’s still facing the same issue: turning product approvals and trial updates into revenue before the market looks again at its cash position.
